At Johnson & Johnson, we have a legacy in HIV that spans over 25 years. We are excited to once again join the global HIV community for the 22nd International AIDS Conference, working side by side to #makeHIVhistory.

Blending Heart, Science and Ingenuity

Learn how we are blending heart, science and ingenuity to change the trajectory of health for those affected by HIV.

Champions of Science

Today, 30 years later, thanks to the work of the global community, we have transformed HIV into a manageable condition that’s treatable with one pill, once a day. Living a long, healthy life with HIV was once a dream but now is a reality for millions.

Stopping HIV requires constant innovation and global collaboration. Some of the world’s best scientists and most engaged health advocates are involved in advancing HIV prevention. Janssen is united with them to find a preventive vaccine and help bring a stop to HIV.

Vaccination is widely recognized as the world’s most successful and cost-effective health intervention. Today there are more than 30 infectious diseases that are vaccine-preventable. Our dream is that HIV will be one of the next, and we will work tirelessly to achieve it.

At Johnson & Johnson we are determined to combine heart, science and ingenuity to do more for people living with HIV. For the past 10 years we have been working to develop an HIV vaccine that could put an end to the pandemic for good. You have my promise that all of us at Johnson & Johnson will not rest until we defeat HIV. Together, we will make HIV history.

While controlling HIV is paramount, today the development of anti-HIV drugs also focuses on improving the lives of patients. Single-tablet regimens simplify dosing regimens and have the potential to support patient adherence and, ultimately, the effectiveness of treatment.

Janssen’s continuing commitment to advance the therapeutic options for people with HIV will benefit patients around the world, but we’re not losing sight of our ultimate goal—to find a cure. We don’t want people with HIV to have to take lifelong therapy, and we continue to explore approaches that have the potential to provide long-term remission from the infection, or full viral eradication.

We partner with many organizations across the globe to provide effective prevention and care programs for people living with HIV and at-risk populations. Working together, we are proud to expand access to vital HIV services in affected communities.

Innovation and Progress Over the Years

Johnson & Johnson and its Janssen Pharmaceutical Companies stand united with the global community to make an HIV-free world a reality.

The Discovery

Scientists discover the virus that causes AIDS.

The World Gathers

The first International AIDS Conference (IAC) takes place.

The Declaration

The World Health Organization declared December 1 to be World AIDS Day.

First Treatment Guidelines Are Issued

The U.S. Centers for Disease Control and Prevention (CDC) issues the first national treatment guidelines for the use of ARV therapy in adults and adolescents.

Region is the World's Epicenter of HIV/AIDS

Approximately 3.5 million new infections occur in sub-Saharan Africa.

Johnson & Johnson Launches GAPP

In 2006, Johnson and Johnson launched the Global Access and Partnerships Program, a global HIV drug access program.

Janssen Medicine Gets Approval in the U.S.

Janssen’s novel protease inhibitor is approved in the U.S.

NNRTI Gets the Green Light

Janssen’s non-nucleoside reverse transcriptase inhibitor (NNRTI) is approved in the E.U. and U.S.

Number of People Receiving Treatment for HIV Grows

WHO estimates 5.2 million people receiving treatment for HIV.

Janssen Announces Exciting Agreement

Janssen and IAVI enter into an agreement to develop a preventive HIV vaccine based on Janssen's AdVac® adenovirus vector technology.

Janssen Partners With EGPAF

Janssen partners with The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and the Partnership for Supply Chain Management System (PFSCMS) to implement New Horizons Advancing Pediatric HIV Care Collaborative.

A Drug Donation Program

Janssen announces first-of-its kind drug donation program for HIV treatment-experienced children.

A Goal Is Set

UNAIDS sets 90-90-90 goals in a bid to end the AIDS epidemic.

Drugs Become More Affordable

Agreement in 112 countries to manufacture generic versions of Janssen's NNRTI.

Collaborations Continue

Janssen announces expanded collaboration with International Partnership for Microbicides for Development and Commercialization of NNRTI for prevention of sexual transmission of HIV.

A New Study Has Promise

Study published in Science highlights potential of investigational preventive vaccine regimen.

Clinical Trial Phase

International Phase I/IIa clinical trial commences to evaluate safety and immunogenicity of Janssen’s HIV preventive vaccine regimen in healthy, HIV-uninfected volunteers.

A Global Promise

Major new global commitments to end HIV infection in adolescent girls and women announced.

A Step Forward in Developing Countries

License granted for Janssen’s protease inhibitor to be developed and commercialized in a number of developing countries to support HIV prevention in women.

A Call for Global Collaboration

The historic challenge of finding an HIV vaccine requires global collaboration.

Janssen’s Preventative Vaccine Trials Progress

First efficacy study of investigational ‘global vaccine' for the prevention of HIV-1 is initiated.

1983

1985

1988

1991

2002

2006

2006

2008

2010

2012

2013

2013

2014

2014

2014

2015

2015

2015

2015

2017

2018

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue